417 related articles for article (PubMed ID: 24503243)
1. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
2. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Whiteley J; Iyer S; Candrilli SD; Kaye JA
Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
[TBL] [Abstract][Full Text] [Related]
9. [Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
González Rosa V; Gutiérrez Nicolás F; Gavira Moreno R; Viña Romero MM; Moreno Carvajal MT; Gázquez Pérez R
Farm Hosp; 2013; 37(6):434-40. PubMed ID: 24256006
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
12. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.
Chen TC; Chen LC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):172-81. PubMed ID: 24242992
[TBL] [Abstract][Full Text] [Related]
13. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
[TBL] [Abstract][Full Text] [Related]
14. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
16. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Signorovitch J; Ayyagari R; Reichmann WM; Wu EQ; Chen L
Cancer Treat Rev; 2014 Mar; 40(2):285-92. PubMed ID: 24112812
[TBL] [Abstract][Full Text] [Related]
17. [Response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia].
Ibarra-Hernández A; Sosa-Quintero LS; Garcés-Ruiz OM; Aguilar-López LB; Rubio-Jurado B; Vega-Ruiz A
Rev Med Inst Mex Seguro Soc; 2014; 52(3):266-9. PubMed ID: 24878084
[TBL] [Abstract][Full Text] [Related]
18. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Kantarjian H; Cortes J
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
[TBL] [Abstract][Full Text] [Related]
20. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
